232 related articles for article (PubMed ID: 25644612)
1. Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study.
Klingel R; Heibges A; Fassbender C
Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):46-50. PubMed ID: 25644612
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
Klingel R; Heibges A; Fassbender C
Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
[TBL] [Abstract][Full Text] [Related]
3. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.
Klingel R; Heibges A; Fassbender C;
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214
[TBL] [Abstract][Full Text] [Related]
4. Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease.
Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):8-13. PubMed ID: 25672934
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
Leebmann J; Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Maerz W; Lehmacher W; Heibges A; Klingel R;
Circulation; 2013 Dec; 128(24):2567-76. PubMed ID: 24056686
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
Hohenstein B; Julius U; Lansberg P; Jaeger B; Mellwig KP; Weiss N; Graehlert X; Roeder I; Ramlow W
Atheroscler Suppl; 2017 Nov; 30():180-186. PubMed ID: 29096835
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Leebmann J; Lehmacher W; Kamstrup PR; Nordestgaard BG; Maerz W; Noureen A; Schmidt K; Kronenberg F; Heibges A; Klingel R;
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2019-27. PubMed ID: 27417585
[TBL] [Abstract][Full Text] [Related]
9. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.
Groß E; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():226-32. PubMed ID: 25936330
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects.
Schmitz G; Orsó E
Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):21-5. PubMed ID: 25708587
[TBL] [Abstract][Full Text] [Related]
11. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.
Schampera S; Fischer S; Weiss N; Julius U
Atheroscler Suppl; 2015 May; 18():209-14. PubMed ID: 25936328
[TBL] [Abstract][Full Text] [Related]
12. Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels.
Julius U; Tselmin S; Schatz U; Fischer S; Birkenfeld AL; Bornstein SR
Atheroscler Suppl; 2019 Dec; 40():1-7. PubMed ID: 31818437
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a).
Poller WC; Dreger H; Morgera S; Berger A; Flessenkämper I; Enke-Melzer K
Atheroscler Suppl; 2015 May; 18():187-93. PubMed ID: 25936325
[TBL] [Abstract][Full Text] [Related]
14. Actual situation of lipoprotein apheresis in Saxony in 2013.
Emmrich U; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():215-25. PubMed ID: 25936329
[TBL] [Abstract][Full Text] [Related]
15. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.
Schatz U; Tselmin S; Müller G; Julius U; Hohenstein B; Fischer S; Bornstein SR
Atheroscler Suppl; 2017 Nov; 30():246-252. PubMed ID: 29096845
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy - successful treatment with lipoprotein apheresis.
Heigl F; Hettich R; Mauch E; Klingel R; Fassbender C
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):50-54. PubMed ID: 28160245
[TBL] [Abstract][Full Text] [Related]
17. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern.
von Dryander M; Fischer S; Passauer J; Müller G; Bornstein SR; Julius U
Atheroscler Suppl; 2013 Jan; 14(1):39-44. PubMed ID: 23357139
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study.
Poller WC; Berger A; Dreger H; Morgera S; Enke-Melzer K
Atheroscler Suppl; 2017 Nov; 30():174-179. PubMed ID: 29096834
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland.
Mickiewicz A; Marlega J; Kuchta A; Bachorski W; Cwiklinska A; Raczak G; Gruchala M; Fijalkowski M
J Clin Apher; 2021 Jun; 36(3):370-378. PubMed ID: 33386762
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Hohenstein B; Roeseler E; Heigl F; Grützmacher P; Blume H; Klingel R; Vogt A;
Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
